GT Biopharma (NASDAQ:GTBP) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of GT Biopharma (NASDAQ:GTBP) from a hold rating to a sell rating in a research report sent to investors on Saturday.

GT Biopharma Price Performance

Shares of GTBP opened at $0.80 on Friday. The firm has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $2.14. The stock has a market cap of $2.85 million, a PE ratio of -0.20 and a beta of 1.37. GT Biopharma has a 1-year low of $0.63 and a 1-year high of $4.10.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.13. As a group, sell-side analysts expect that GT Biopharma will post -6.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GT Biopharma

A hedge fund recently raised its stake in GT Biopharma stock. Bank of Montreal Can boosted its position in shares of GT Biopharma, Inc. (NASDAQ:GTBP) by 531.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,530 shares of the company’s stock after acquiring an additional 77,879 shares during the quarter. Bank of Montreal Can owned 2.83% of GT Biopharma worth $331,000 at the end of the most recent quarter. Institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.